fda compounded tirzepatide warning 2024 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Warning Letter Breakdown: Sterility

Negative experiences related to body weight, whether from healthcare professionals, employers, or social situations, can trigger and worsen depressive symptoms

Photo Credit: Shutterstock GLP-1 Dropout Rates: Why So Many People Quit Despite the hype, real-world adherence to GLP-1 medications is surprisingly low

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), produces modest increases in heart rate that clinicians and patients should understand

That dual mechanism is why tirzepatide is studied as its own category within metabolic pharmacology rather than lumped in with single-pathway agonists

It is because of this that you should keep in touch with a trusted clinic so that you can get updates of how these clinical trials are progressing